Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 12;17(1):154.
doi: 10.1186/s13195-025-01805-8.

Cerebral small vessel disease in memory center patients with dementia with lewy bodies and Alzheimer's disease

Bommarito Giulia  1 , Griffa Alessandra  2   3 , Michel Patrik  4 , Hall Caroline  2 , Salvioni Chiabotti Paolo  2 , Pistocchi Silvia  5 , Alemán-Gómez Yasser  5 , Damian Daniel  2 , Jreige Mario  6 , Prior John O  6 , Dunet Vincent  5 , Rouaud Olivier  2 , Hagmann Patric  5 , Allali Gilles  2
Affiliations

Cerebral small vessel disease in memory center patients with dementia with lewy bodies and Alzheimer's disease

Bommarito Giulia et al. Alzheimers Res Ther. .

Abstract

Introduction: Cerebral small vessel disease (CSVD) is a common co-pathology in patients with dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). A comprehensive characterization of CSVD load in DLB and AD patients referred to a memory center is lacking.

Methods: In this retrospective study, we collected data from patients with a clinical DLB diagnosis or clinico-biological AD diagnosis, evaluated at our memory center. They were assessed for CSVD MRI features, including enlarged perivascular spaces (PVS), presence of cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy (HTNA). Differences in CSVD features between AD and DLB and across clinical stages were investigated. Regression models were used to evaluate the association between (i) cerebrovascular risk factors (CVRF) and HTNA, and (ii) CSVD features and cognition as expressed by Montreal Cognitive Assessment (MoCA).

Results: We included 71 DLB (76.8 ± 7.4 years old, 25 females) and 71 age- and sex-matched AD patients (and 75.2 ± 5.3 years old, 27 females). Probable CAA, according to current Boston 2.0 criteria, was observed in 22.5% of DLB and 35.2% of AD patients, while any (probable + possible) CAA rate was higher in the two groups (71.8% and 91.5%, respectively). A moderate/severe HTNA was present in 45% of DLB and 28.2% of AD patients. When comparing the two groups, DLB presented with higher HTNA score (p =.012), while AD patients had higher prevalence of any CAA (p =.002). Patients with DLB had a greater PVS burden in the basal ganglia (p =.011) and centrum semiovale (p =.004) and higher number of deep microbleeds (p =.004). Certain HTNA-related features were more pronounced at dementia stage, with respect to mild cognitive impairment. No association was observed between CVRF and HTNA. Regarding the association between CSVD and cognition, only deep microbleeds count was related to MoCA in DLB patients.

Discussion: DLB or AD patients present with high CSVD burden and differ in terms of features and subtype. Patients with DLB present with increased HTNA, PVS load and deep microbleeds, while patients with AD present with a higher any CAA prevalence. CSVD might impact global cognition.

Keywords: AD; Alzheimer’s disease; CSVD; Cerebral small vessel disease; DLB; Dementia with lewy bodies; Perivascular spaces.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: G. Bommarito: reports no disclosures relevant to the manuscript. A. Griffa: reports no disclosures relevant to the manuscript. P. Michel: reports no disclosures relevant to the manuscript. C. Hall: reports no disclosures relevant to the manuscript. P. Salvioni-Chiabotti: reports no disclosures relevant to the manuscript. S. Pistocchi: reports no disclosures relevant to the manuscript. Y. Aleman-Gomez: reports no disclosures relevant to the manuscript. D. Damian: reports no disclosures relevant to the manuscript. M. Jreige: reports no disclosures relevant to the manuscript. J. O. Prior: reports no disclosures relevant to the manuscript. V. Dunet: reports no disclosures relevant to the manuscript. O. Rouaud: reports no disclosures relevant to the manuscript. P. Hagmann: reports no disclosures relevant to the manuscript. G. Allali reports no disclosures relevant to the manuscript.

Figures

Fig. 1
Fig. 1
A. Prevalence (%) of probable or any CAA (purple) and HTNA (yellow) in DLB and AD patients. B. Number (N) of perivascular spaces at the level of basal ganglia (BG) and centrum semiovale (CSO) in DLB and AD
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Niedowicz DM, Nelson PT, Murphy MP. Alzheimers Disease: Pathological Mechanisms and Recent Insights [Internet]. Curr. Neuropharmacol. 2011. pp. 674–84. Available from: http://www.eurekaselect.com/article/20860 - PMC - PubMed
    1. Attems J, Jellinger KA. The overlap between vascular disease and alzheimer’s disease - lessons from pathology. BMC Med. 2014;12:1–12. - PMC - PubMed
    1. Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel disease to Alzheimer’s disease dementia and cognitive function in elderly people: a cross-sectional study. Lancet Neurol [Internet]. 2016;15:934–43. Available from: 10.1016/S1474-4422(16)30029-1 - PMC - PubMed
    1. Jäkel L, De Kort AM, Klijn CJM, Schreuder FHBM, Verbeek MM. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimer’s Dement. 2022;18:10–28. - PMC - PubMed
    1. Jellinger KA. Significance of cerebral amyloid angiopathy and other co-morbidities in lewy body diseases. J Neural Transm. 2021;128:687–99. - PubMed

MeSH terms